Heptares and AstraZeneca: combining forces in novel approaches to drug discovery

When AstraZeneca was looking for alternative approaches to finding compounds for some particularly difficult targets, we teamed up with UK biotech Heptares Therapeutics.

Heptares uses its proprietary Stabilised Receptor or StaR® technology to enable the techniques of structure-based and fragment-based drug discovery to be applied to difficult G protein-coupled receptor (GPCR) targets that our scientists have nominated. By combining our expertise, technologies and capabilities, this collaboration allows for a novel way of finding hits that we would otherwise not have been able to do, in order to bring new medicines to people who need them.

 

 

Related articles